- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00100126
APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat
A Phase III, Investigator Blind, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of APC-231 Sprinkle QD for 7 Days vs Penicillin VK 10 mg/kg QID for 10 Days in Pediatric Patients With Streptococcus Pyogenes
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
South Carolina
-
Simpsonville, South Carolina, United States, 29681
-
-
Utah
-
Salt Lake City, Utah, United States, 84121
- Institute for Neuroscience Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Give informed consent, assent, and documentation of patient authorization for disclosure of study results.
Since all patients are below the legal age of consent, assent from the patient must be obtained (as applicable following state regulations) and written informed consent obtained from the parent or legal guardian.
- Age > = 6 months -12 years.
A clinical diagnosis of acute tonsillitis and/or pharyngitis defined as having the clinical signs and symptoms compatible with tonsillitis and/or pharyngitis, including sore throat or difficulty feeding or swallowing or irritability that suggests the presence of a sore throat with at least one of the following:
- Tonsillar or pharyngeal exudate
- Tender cervical lymph nodes
- Fever or history of fever treated with antipyretics
- Odynophagia
- Uvular edema
- Pharyngeal Erythema of moderate or greater intensity
- Elevated white blood cell (WBC) >12,000/mm3 or 10% bands
- Red tongue and prominent papillae (Strawberry tongue)
- A positive rapid screening test for S. pyogenes (enzyme immunoassay; SiGNIFY™ Strep A Test).
- Patient is an appropriate candidate for oral antibiotic therapy and can swallow the study dosage forms.
Females must be non-lactating and:
- If of childbearing potential and sexually active, the patient must have a negative prestudy urine pregnancy test and be utilizing acceptable birth control methods throughout the study.
Exclusion Criteria:
Chronic or recurrent (two weeks duration two times per year) odynophagia or enlarged tonsils secondary to viral or proven bacterial etiology.
- The need for hospitalization or I.V. antimicrobial therapy.
- Pharyngitis known or suspected to be due to a pathogen resistant to beta-lactam antimicrobials.
- Patients who are known carriers of S. pyogenes.
- Previous allergy, serious adverse reaction to, or intolerance to, penicillin or any other member of the beta-lactam class of antimicrobials.
- Any serious illness or concomitant condition that the investigator judges would preclude the study evaluations or make it unlikely that the course of study therapy and follow-up could be completed. This would also include:
- Any rapidly progressive underlying disease with a shortened life expectancy.
- The inability to swallow the study dosage form.
- Unable to understand the requirements of the study.
- Neutropenia (<1000 PMNs/mm3) or other known immunocompromised state.
Hard chills or rigors.
- Seizure disorder or lowered seizure threshold. This does not exclude children with previous febrile seizures.
- Psychiatric condition requiring use of major tranquilizers.
- Pregnancy or nursing.
- Expectation that additional effective systemic antibacterials would be required for any condition during the duration of the study.
- Current drug or alcohol abuse.
- Receipt of any experimental drug or medical device within the previous 30 days (or are scheduled to receive any other experimental procedures during the study period).
- Previous treatment under this protocol.
- Systemic antimicrobial therapy with benzathine penicillin within 30 days or azithromycin within 14 days.
- Hospitalization within the month prior to study admission, during which antibacterial therapy was administered.
- The presence of clinically significant hematologic conditions or cardiac valvular disease.
- History of cardiovascular disease, renal disease, or neurological disease secondary to previous infection with S. pyogenes.
- Probenecid treatment or systemic steroids during the duration of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Bacteriological outcome at Test of Cure Visit
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety
|
Bacteriological outcome at Late Post Therapy Visit
|
Clinical Outcomes
|
Collaborators and Investigators
Investigators
- Study Director: Susan Clausen, PhD, Advancis Pharmaceutical Corp
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 231.301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharyngitis
-
Vastra Gotaland RegionGöteborg University; James Cook University, Queensland, AustraliaCompletedTonsillitis | Pharyngitis | Sore Throat | Streptococcus Pharyngitis | Pharyngitis BacterialSweden
-
Andrew SteerNational Health and Medical Research Council, Australia; Queen Fabiola Children... and other collaboratorsCompletedBacterial Infections | Gram-Positive Bacterial Infections | Strep Throat | Streptococcus Pharyngitis | Streptococcus Pyogenes Pharyngitis | Streptococcus Pyogenes Infection | Group A Streptococcus: B Hemolytic Pharyngitis | Group A Streptococcal InfectionAustralia
-
Luminex CorporationCompletedPharyngitis BacterialUnited States
-
Hamilton Health Sciences CorporationRecruiting
-
University of Wisconsin, MadisonNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Oman Medical Speciality BoardCompleted
-
Megainpharm GmbHTerminated
-
Dentaid SLMethodexRecruiting
-
Northwell HealthIcahn School of Medicine at Mount Sinai; Agency for Healthcare Research and...CompletedPneumonia | Strep PharyngitisUnited States
-
Dalin Tzu Chi General HospitalRecruitingChronic PharyngitisTaiwan
Clinical Trials on Amoxicillin Pulsatile Release Multiparticluate Sprinkle
-
Advancis Pharmaceutical CorporationCompletedTonsillitis | PharyngitisUnited States
-
AbbottCompletedPediatric EpilepsyUnited States
-
Prof. Arie LevineCompletedUlcerative Colitis (UC)United States, Israel, Canada
-
University of Wisconsin, MadisonThrasher Research FundCompleted
-
Cliniques universitaires Saint-Luc- Université...UnknownBisphosphonate-Associated Osteonecrosis of the JawBelgium
-
Prof. Arie LevineTerminated
-
Shandong UniversityShandong Provincial Hospital; Liaocheng People's Hospital; Binzhou People's Hospital and other collaboratorsUnknownHelicobacter Pylori Infection | Antimicrobial Susceptibility TestingChina
-
Universita degli Studi di CataniaCompleted
-
Ferring PharmaceuticalsCompleted